Boehringer Ingelheim Named to Working Mother’s “100 Best Companies for Working Mothers” List

RIDGEFIELD, Conn.--(BUSINESS WIRE)--Boehringer Ingelheim announced today that it has been named to the 2014 Working Mother 100 Best Companies List. The company was awarded for outstanding leadership in establishing policies, programs and corporate culture that support working mothers, including child care, flexible work arrangements, paid parental leave and advancement of women. Boehringer Ingelheim was also measured on access to and usage of family-friendly programs. “We are committed to providing flexible work environments and policies for working parents here at Boehringer Ingelheim,” said Nancy Di Dia, Executive Director and Chief Diversity Officer, Boehringer Ingelheim. About Diovan Hct (Valsartan-Hydrochlorothiazide) without Rx “It’s an honor to be recognized among many other high caliber companies for our culture as we continue to explore new and beneficial work/life policies for our employees.” In addition to Boehringer Ingelheim’s generous paid time off policies, the company also places great emphasis on its health and wellness program. Diprolene (Betamethasone) with no prescription The company provides onsite occupational health services, a fitness center for employees and their spouse/partner, healthy dining options, wellness screenings, indoor/outdoor walking paths, disease management resources, and a nurse hotline. “The Working Mother 100 Best Companies are the leaders in the advancement of women by supporting their need to integrate family and work successfully,” said Carol Evans, President, Working Mother Media. Buy Diflucan (Fluconazole) with no prescription “We are thrilled to honor the U.S. About Desogen without Rx companies that put words into action and build family-friendly cultures on the foundation of thoughtful policies and effective programs. Buy Soy online Women now make up 50% of our workforce. http://futurepharmaceuticals.wordpress.com We need to make sure they have the support to be outstanding moms as well as great employees." Jennifer Owens, editorial director of Working Mother Media, noted, “In its 29th year, the Working Mother 100 Best Companies are a powerful reminder of how great companies can and do create supportive workplaces for their employees. All employers would do well to follow their lead if they want to attract and retain top talent.” The complete list of the 2014 Working Mother 100 Best Companies can be found here. About Boehringer Ingelheim The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. Social responsibility is a central element of Boehringer Ingelheim s culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors. In 2013, Boehringer Ingelheim achieved net sales of about €14.1 billion. R&D expenditure corresponds to 19.5% of net sales. For more information, please visit us.boehringer-ingelheim.com, and follow us on Twitter at twitter.com/boehringerus. About Working Mother Media Working Mother Media, a division of Bonnier Corporation (bonnier.com), is the publisher of Working Mother magazine and its companion website workingmother.com, and is home to the Working Mother Research Institute. The National Association for Female Executives (nafe.com ) and Diversity Best Practices (diversitybestpractices.com) are also units within WMM. Working Mother Media’s mission is to serve as a champion of culture change. Working Mother magazine is the only national magazine for career-committed mothers. Follow us on Facebook, Twitter, LinkedIn and Pinterest.

Riassunto Terumo BCT apre uno stabilimento di produzione in Vietnam

. http://futurepharmaceuticals.wordpress.com Buy Hard On (Sildenafil Citrate) without prescription LAKEWOOD, Colorado--(BUSINESS WIRE)--Terumo BCT, una societ`a leader di portata globale specializzata in tecnologie per componenti ematici, aferesi terapeutica e cellule, ha annunciato quest oggi l apertura di uno stabilimento di produzione con una superficie di 91.440 metri quadri nei pressi di Ho Chi Minh City, Vietnam. About Xylocaine (Lidocaine) with free prescription Lo stabilimento di produzione da 100 milioni di dollari sosterr`a l espansione delle attivit`a di Terumo BCT a livello globale. About Co-amoxiclav All avvio delle operazioni di produzione verso gli inizi del 2015, il nuovo stabilimento accrescer`a la capacit`a produttiva della societ`a. Fatti salienti: Terumo BCT `e un produttore di portata globale di dispositivi medicali con sede generale a Lakewood, Colorado Le sedi generali regionali sono ubicate a: Bruxelles, Buenos Aires, Hong Kong e Tokyo Il testo originale del presente annuncio, redatto nella lingua di partenza, `e la versione ufficiale che fa fede. Buy Muscle Recovery online About Cialis Sublingual (Tadalafil) with free Rx Le traduzioni sono offerte unicamente per comodit`a del lettore e devono rinviare al testo in lingua originale, che `e l unico giuridicamente valido.

New Studies Presented at Alzheimer’s Association International Conference Demonstrate Diagnostic Value of GE Healthcare’s [18F]Flutemetamol

COPENHAGEN, Denmark--(BUSINESS WIRE)--New study data presented today at the Alzheimer’s Association International Conference® 2014 (AAIC®) showed that a positive [18F]flutemetamol PET scan for brain amyloid was a highly significant predictor of progression from amnestic Mild Cognitive Impairment (aMCI) to probable Alzheimer’s disease (pAD).1 A second study further demonstrated the diagnostic value of [18F]flutemetamol in confirming the presence of neuritic amyloid in those patients with early onset dementia.2 [18F]Flutemetamol is GE Healthcare’s investigational radiopharmaceutical product for PET imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive impairment. “Collectively, these data demonstrate the diagnostic value of [18F]flutemetamol and add to the growing body of evidence that it can help physicians identify the histopathology associated with an Alzheimer’s disease diagnosis in specific patients,” said Ger Brophy, PhD, Chief Technology Officer, Life Sciences, GE Healthcare. “If and when approved in the European Union, [18F]flutemetamol will be an important tool to support assessments of patients with cognitive disorders, as well as being a valuable research tool in the hunt for therapies to combat Alzheimer’s.” Use of [18F]Flutemetamol PET Scans as Indicator of Progression from Amnestic Mild Cognitive Impairment to Probable Alzheimer’s Disease In the study, 232 participants with MCI, a diagnosis characterized by cognitive deficits not severe enough to impact daily functioning and thus not meeting the definition of dementia, received a [18F]flutemetamol injection and underwent brain scans. The study showed those with positive VIZAMYL scans were approximately 2.5 times more likely to convert to pAD than those with negative scans. About Diovan Hct (Valsartan-Hydrochlorothiazide) without Rx The ability of positive [18F]flutemetamol PET images to identify aMCI patients at higher risk of progressing to AD could potentially allow for better patient evaluation and management, and support patient stratification in enrolment into clinical trials for disease modifying drugs “These findings demonstrate the potential role of [18F]flutemetamol in stratifying those patients at higher risk of developing Alzheimer’s disease, beyond its use as a diagnostic tool,” said David Wolk, MD, Assistant Director, Penn Memory Center and Lead Investigator of the study. Diprolene (Betamethasone) with no prescription “In addition to providing patients with potentially important prognostic information about their likelihood of developing dementia, identifying high risk patients could help guide physicians’ recommendations for patient monitoring, care plans and use diagnostic resources. Buy Diflucan (Fluconazole) with no prescription These are exciting results, but we need further research to fully understand how this might be used in clinical practice.” Diagnostic Value of [18F]Flutemetamol) in Early Onset Dementia In this study, 80 patients with early onset dementia (younger than age 70), and with physician diagnostic confidence less than 90 percent, underwent [18F]flutemetamol PET scans which were assessed as either amyloid positive or negative. About Desogen without Rx Clinical diagnosis and diagnostic confidence was determined, both before and after disclosure of the scan results. Buy Soy online This study demonstrated that the use of [18F]flutemetamol increased diagnostic confidence for physicians, and in many patients, helped to confirm or exclude the diagnosis of Alzheimer’s disease and lead to changes in management. “Early and accurate diagnoses may have implications for both prognosis and treatment among patients with early onset dementia,” said Dr. http://futurepharmaceuticals.wordpress.com Marissa Zwan, VU University Medical Center, Amsterdam and Lead Investigator of the study. “Greater diagnostic confidence supports better patient management and helps physicians to determine appropriate treatment options, as well as helping patients and caregivers to plan for the future.” The data showed that 20 percent of patients had a change in diagnosis following review of the [18F]flutemetamol scan. In particular, for those patients diagnosed with Alzheimer’s disease prior to a [18F]flutemetamol scan and who had an amyloid negative result, clinical diagnosis changed in 12 of 15 patients. Overall, confidence in diagnosis significantly increased from 67(±12) percent to 90(±16) percent after disclosing PET results. Additionally, in 48 percent of patients, 18F]flutemetamol PET results led to a change in patient healthcare management (i.e. medication changes, additional care). In October 2013, [18F]flutemetamol received approval from the U.S. Food and Drug Administration, where it is marketed as VIZAMYL™, for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline. VIZAMYL is for diagnostic use only and should be used in conjunction with a clinical evaluation. VIZAMYL is not licensed in any market for estimating the risk of MCI progression to clinical AD. In June 2014, [18F]flutemetamol received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending the granting of a marketing authorization for PET imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive impairment. It is not yet approved for use in Europe or Japan. GE HEALTHCARE’S COMMITMENT TO IMAGING RESEARCH [18F]Flutemetamol is one component of a broad portfolio of investigational diagnostic solutions that GE Healthcare is currently developing in the neurology field. GE Healthcare is taking a comprehensive approach to understanding dementia and AD through its ongoing research to uncover the causes, risks, and physical effects of the disease. GE Healthcare offers a broad portfolio of imaging resources including cyclotrons and chemistry systems to manufacture PET imaging agents, PET and MR scanners to scan patients, and is developing image analysis software to provide quantification, optimized visualization and reporting tools. Additionally, GE Healthcare is collaborating with the pharmaceutical industry to assist in their development of the next generation of therapies. To that end, we are working with potential partners in the industry to understand their strategic needs, and helping to provide imaging support for clinical trials of therapeutic agents. ABOUT GE HEALTHCARE GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For our latest news, please visit newsroom.gehealthcare.com 1 Wolk DA, Duara R, Sadowsky C, et al. : [18F]Flutemetamol Amyloid PET Imaging: Outcome of Phase III Study in Subjects with Amnestic Mild Cognitive Impairment after 3 Year Follow Up. Data presented at Alzheimer’s Association International Conference® 2014 2 Zwan MD, Bouwman FH, Lammertsma AA, et al. Clinical Impact of [18F]Flutemetamol PET in Young Onset Dementia. Data presented at Alzheimer’s Association International Conference® 2014

The 25th Neuronal Plasticity Prize of the Fondation Ipsen Has Been Awarded to Barry J. Everitt (Cambridge, UK), George F. Koob (La Jolla, USA) and Michel Le Moal (Bordeaux, France)

PARIS--(BUSINESS WIRE)--The 25th annual Neuronal Plasticity Prize of the Fondation Ipsen has been awarded to three researchers for their pioneer works in the domain of “Neuropsychology of drug addiction”: Barry J. Everitt (University of Cambridge, Cambridge, UK), George F. Koob (The Scripps Research Institute, La Jolla, USA) and Michel Le Moal (Inserm U862, Bordeaux, France). About Vermox (Mebendazole) with free prescription The €60,000 prize was awarded on July 8, 2014 at the FENS (Federation of European Neuroscience Societies) in Milano by an international jury led by Professor Nikos Logothetis (Max Planck Institute for Biological Cybernetics, T"ubingen, Germany). About the laureates Barry Everitt is Professor and Director of Research, and Provost of the Gates Cambridge Trust, at the University of Cambridge. Viagra (Sildenafil Citrate) without prescription He graduated from Hull University with a B.Sc. Topamax (Topiramate) without prescription in Zoology (1967) and completed his Ph.D. About Ciza with free Rx in behavioural neuroendocrinology at the University of Birmingham Medical School in 1970. Buy Malic Acid Combos online Following formative, postdoctoral neuroscience research at the Karolinska Institutet in Stockholm (1973-1974), he was appointed lecturer, then Reader in Neuroscience in the Department of Anatomy, University of Cambridge. http://futurepharmaceuticals.wordpress.com He moved to the Department of Experimental Psychology in Cambridge in 1995 and was appointed Professor of Behavioural Neuroscience. He was elected a Fellow of the Royal Society in 2007, Fellow of the Academy of Medical Sciences in 2008, and a Member of EMBO in 2014. As a behavioural neuroscientist, Barry Everitt’s research has always been concerned with understanding the neural mechanisms of motivation, learning and memory, especially in the context of drug addiction. His laboratory has made fundamental discoveries on the limbic corticostriatal systems mediating pavlovian and instrumental learning and memory mechanisms that underlie the seeking and taking of addictive drugs. He also has a major interest in the molecular and systems basis of memory reconsolidation of addictive drug and fear memories and the potential of targeting maladaptive memories in the treatment of neuropsychiatric disorders, including addiction. He has been President of the British Association for Psychopharmacology (1992-1994), the European Brain and Behaviour Society (1998-2000), and the European Behavioural Pharmacology Society (2003-2005). He was Editor-in-Chief of the European Journal of Neuroscience (1997-2008) and is a Reviewing Editor for the journal Science. He has received many awards, including the Distinguished Scientific Contribution Award of the American Psychological Association (2011), the Distinguished Scientific Achievement Award of the European Behavioural Pharmacology Society (2011), and the FENS-EJN Award of the Federation of European Neuroscience Societies (2012). George F. Koob, Ph.D. is Director of the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health, Washington, DC. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 600 peers reviewed papers and several books including the Neurobiology of Addiction, a comprehensive treatise on emerging research in the field. Michel Le Moal is Professor Emeritus of Neuroscience at the University of Bordeaux. He graduated in Medicine (M.D. in 1962), in philosophy-sociology and in natural sciences and then in neurology (1967) and psychiatry (1968). He completed a Doctorate in Science at the University of Bordeaux in 1974. In parallel with his academic life in Bordeaux, he spent some years as associate researcher or professor in Caltech (Pasadena) first, Jim Olds laboratory (1974-1976) and at the Salk Institute and Scripps Research Institute (San Diego) in Floyd Bloom and George Koob laboratories (1979-1994). In both institutions, he worked on dopamine neurons electrophysiology and then, on the roles of brain CRF and dopamine systems on behavior and drug addiction. His research interests concern behavior and adaptive processes, their biological foundations and experimental psychopathology a discipline he tried to promote. The concept of individual vulnerability to behavioral pathologies has been at the center of his working hypotheses. Michel Le Moal has been the founder and director of several research laboratories in CNRS and Inserm and finally of the Magendie Institute for Neuroscience and Biological Psychiatry in Bordeaux. He is an elected fellow of the French National Academy of Sciences About the Neuronal Plasticity Prize Founded in 1990, the Neuronal Plasticity Prize of La Fondation Ipsen has been awarded to renowned specialists: Albert Aguayo (Montr eal, 1990), Anders Bj"orklund (Lund, 1990), Fred Gage (La Jolla, 1990), Ursula Bellugi (La Jolla, 1991), Wolf Singer (Frankfurt, 1990), Torsten Wiesel (New York, 1991), Philippe Ascher (Paris, 1992), Kjell Fuxe (Stockholm, 1992), Terje Lomo (Oslo, 1992), Per Andersen (Oslo, 1993), Masao Ito (Wako Saitama, 1993), Constantino Sotelo (Paris, 1993), Mariano Barbacid (Princeton, 1994), Yves Barde (Planegg-Martinsried, 1994), Hans Thoenen (Planegg-Martinsried, 1994), Jacques Mehler (Paris, 1995), Brenda Milner (Montreal, 1995), Mortimer Mishkin (Bethesda, 1995), Friedrich Bonhoeffer (Tubingen, 1996), Corey Goodman (Berkeley, 1996), Marc Tessier-Lavigne (San Francisco, 1996), Antonio Damasio (Iowa City, 1997), Richard Frackowiac (London, 1997), Michael Merzenich (San Francisco, 1997), Heinrich Betz (Frankfurt, 1998), Gerald Fischbach (Boston, 1998), Uel McMahan (Stanford, 1998), Masakazu Konishi (Pasadena, 1999), Peter Marler (Davis, 1999), Fernando Nottebohm (Millbrook, 1999), Tomas H"okfelt (Stockholm, 2000), Lars Olson (Stockholm, 2000), Lars Terenius (Stockholm, 2000), Albert Galaburda (Boston, 2001), John Morton (Londres, 2001), Elisabeth Spelke (Cambridge, USA, 2001), Arturo Alvarez-Buylla (San Francisco, 2002), Ronald Mc Kay (Bethesda, 2002), Sam Weiss (Calgary, 2002), Francois Clarac (Marseille, 2003), Sven Grillner (Stockholm, 2003), Serge Rossignol (Montr eal, 2003), James Gusella (Boston, 2004), Jean-Louis Mandel (Strasbourg, 2004), Huda Y. Zoghbi (Houston, 2004), Ann Graybiel (Cambridge, USA, 2005), Trevor Robbins (Cambridge, UK, 2005), Wolfram Schultz (Cambridge, UK, 2005, Eckhart D. Gundelfinger (Magdeburg, 2006), Mary B. Kennedy (Pasadena, 2006), Morgan Sheng (Cambridge, USA, 2006), Nikos K. Logothetis (T"ubingen, 2007), Keiji Tanaka (Wako, 2007), Giacomo Rizzolati (Parma, 2007), Jean-Pierre Changeux (Paris, 2008), Peter W. Kalivas (Charleston 2008), Eric J. Nestler (Dallas, 2008), Alim-Louis Benabid (Grenoble, 2009), Apostolos P. Georgopoulos (Minneapolis, 2009) , Miguel A. L. Nicolelis (Durham, 2009), Thomas Insel (Bethesda, 2010), Bruce Mc Ewen (New York, 2010) and Donald Pfaff (New York, 2010), Helen Neville (Eugene, 2011), Isabelle Peretz (Montreal, 2011), Robert Zatorre (Montreal, 2011), Catherine Dulac (Boston, 2012), Richard G. Morris (Edinburgh, 2012), J. David Sweatt (Birmingham, 2012), Tim V.P. Bliss (London, 2013), Richard G. M. Morris (Edinburgh, 2013), Yadin Dudai (Rehovot, 2013). The jury: Albert Aguayo (Montreal General Hospital, Montr eal, Canada), Jo"el Bockaert (Institut de G enomique Fonctionnelle, Montpellier, France), Alexis Brice (H^opital de la Salp`etri`ere, Paris, France), Stanislas Dehaene (Inserm U562, Orsay, France), Stephen Dunnett (Cardiff University, Cardiff, UK), Kjell Fuxe (Karolinska Institute, Stockholm, Sweden), Christine Petit (Institut Pasteur, Paris, France), Wolf Singer (Max-Planck Institute for Brain Research, Frankfurt, Germany). About the Fondation Ipsen Founded in 1983 under the aegis of the Fondation de France, the Fondation Ipsen is dedicated to contributing to the development and dissemination of scientific knowledge. The long-standing action of the Fondation Ipsen aims to promote the interaction between researchers and clinicians, essential exchanges because of the extreme specialization of these professions. The ambition of the Fondation Ipsen is to initiate a reflection about the major scientific issues of the forthcoming years. The Fondation has developed a significant international network of scientific experts, who meet regularly at Colloques M edecine et Recherche, dedicated to five main themes: Alzheimer s disease, neuroscience, longevity, endocrinology and cancer. Furthermore, since 2007 the Fondation Ipsen has introduced several series of meetings in partnership with the Salk Institute, the Karolinska Institutet, Massachusetts General Hospital, the DMMGF Foundation, as well as with the journals Nature, Cell and Science. The Fondation Ipsen has published over one hundred books and has awarded more than 250 prizes and grants. More information can be found on the website: .fondation-ipsen.org

Vertex Announces Retirement of Peter Mueller, Ph.D.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Peter Mueller, Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company. Dr. Mueller’s retirement will be effective October 31, 2014, following a planned transition period. Dr. About Prilosec (Omeprazole) with free Rx Mueller joined Vertex in 2003 as Chief Scientific Officer and Senior Vice President, Drug Discovery and Innovation. “Peter is a visionary who embodied Vertex’s fearless pursuit of transformational medicines,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. Buy Principen (Ampicillin) with free Rx “I thank Peter for his leadership, innovation and dedication to Vertex over the past decade.” Jeffrey A. Buy Pepcid (Famotidine) with no Rx Chodakewitz, M.D., Vertex’s Senior Vice President of Global Medicines Development and Medical Affairs and Chief Medical Officer, will continue to oversee all global clinical development programs and other related functions and will now assume additional responsibility for Regulatory Affairs and Global Patient Safety. Cefixime with no prescription Vertex expects to appoint a Head of Global Research to oversee the company’s drug discovery efforts following Dr. Buy Hypoallergenic Vitamin C online Mueller’s retirement. About Vertex Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. http://futurepharmaceuticals.wordpress.com In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For four years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. For additional information and the latest updates from the company, please visit .vrtx.com. Vertex s press releases are available at .vrtx.com. Special Note Regarding Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements in the third paragraph of this press release. While Vertex believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, the risks listed under Risk Factors in Vertex s annual report and quarterly reports filed with the Securities and Exchange Commission and available through the company s website at .vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN)

Salix Pharmaceuticals to Combine with Cosmo Technologies to Form Salix Pharmaceuticals, plc

Salix Pharmaceuticals to Combine with Cosmo Technologies to Form Salix Pharmaceuticals, plc

RALEIGH, N.C. & LAINATE, Italy--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (“Salix”) (NASDAQ: SLXP) and Cosmo Pharmaceuticals S.p.A. (“Cosmo”) (SIX: COPN) today announced a definitive merger agreement under which Salix will combine with Cosmo Technologies Limited (“Cosmo Tech”), a subsidiary of Cosmo. Buy Lithobid (Lithium) with free Rx Under the terms of the agreement, Salix will become a wholly-owned subsidiary of Irish domiciled Cosmo Tech, which will change its name to Salix Pharmaceuticals, plc and is expected to have its ordinary shares listed and traded on the NASDAQ Global Select Market. About Lopid (Gemfibrozil) with no prescription The transaction is expected to be modestly accretive to Salix’s earnings per share in 2016 and increasingly accretive thereafter. Salix Pharmaceuticals, plc will own Cosmo’s U.S. Lanoxin (Digoxin) with free prescription patents for rifamycin MMX®, methylene blue MMX® and Uceris®, and have specified rights of negotiation with respect to all products Cosmo or its affiliates seek to develop or commercialize in the U.S. About Butenafine with free Rx In addition, Salix Pharmaceuticals, plc will acquire Cosmo’s patents for rifamycin MMX in Canada, specified Latin American countries, India, China, Japan and the rest of the Far East, excluding Australia and New Zealand, and Cosmo’s patents for Uceris in Japan. Cosmo, the parent company of Cosmo Tech, is a publicly-traded, specialty pharmaceutical company headquartered in Lainate, Italy. Buy Gas/Bloating online Cosmo’s proprietary clinical development pipeline specifically addresses innovative treatments for the gastro-intestinal tract such as inflammatory bowel disease, colon infections and diagnostics for the colon. http://pharmaceuticaljournal.wordpress.com Cosmo is the inventor and developer of Lialda® and Uceris. Transaction Rationale The transaction enhances Salix’s position as a leader in developing and marketing products in the U.S. to treat gastrointestinal disease and disorders and establishes a corporate structure that enhances Salix’s acquisition strategy and organic growth. The transaction: Adds highly complementary product opportunities to Salix’s portfolio Provides substantial opportunities with rifamycin MMX for conditions of the colon, including diverticulitis, a large and unsatisfied market Adds methylene blue MMX to aid in the detection of colon cancer Eliminates Uceris royalties and milestones and modifies the Uceris supply agreement which substantially improves Uceris’ profitability, allowing Salix to capture full value of the existing indication as well as potential future indications Establishes tax efficient corporate structure and increases Salix’s competitive positioning for future M&A and product licensing efforts Carolyn Logan, President and CEO of Salix stated, “Cosmo is an excellent company which we have known for years, so we are very pleased to announce this transaction. Combining with Cosmo Tech makes tremendous strategic and financial sense for us as it further strengthens and consolidates our position as a leader in acquiring, developing and marketing products to treat gastrointestinal disease and disorders. Uceris is an important product in our portfolio and this transaction will improve its profitability as well as that of Salix as a whole. The new corporate structure greatly enhances our ability to compete for licensing deals and acquisitions, and improves the economics of future business development opportunities for Salix. Further, by adding multiple new and complementary product opportunities, to which we will be able to bring our proven expertise in development and commercialization, we expect these new pipeline additions to diversify and grow our future revenue base. We view this transaction as an evolutionary step that should create value and higher returns for our shareholders by bolstering our competitive position in the marketplace, all within an efficient corporate structure that should increase our profitability and accelerate our long term growth.” Alessandro Della Chá, CEO of Cosmo stated, “It was our strategic objective to find the best possible partner to market our products in the U.S., and to have a substantial financial interest in this. This transaction allows two companies that are already leaders in GI to join their different but complementary competencies to create new products that satisfy unmet needs of patients and provide additional value for shareholders.” Transaction Details Upon completion of the merger, shareholders of Salix are expected to own slightly less than 80% of the ordinary shares of Salix Pharmaceuticals, plc and Cosmo is expected to own slightly more than 20%. Shareholders of Salix will receive one ordinary share of Salix Pharmaceuticals, plc in exchange for each share of Salix Pharmaceuticals, Ltd common stock they own at closing. In connection with the merger, Cosmo will continue to supply Uceris to Salix and will also supply rifamycin MMX and methylene blue MMX. Additionally, Cosmo will have the right to designate one director to serve on the board of directors of Salix Pharmaceuticals, plc and will be subject to certain standstill provisions for at least 10 years following the completion of the merger. The transaction, which will be taxable to Salix’s shareholders, is expected to close in the fourth quarter of 2014. In connection with the transaction, Salix will also receive certain rights and protections under a Right of Negotiation and Non-Compete Agreement, which will: (1) give Salix a right of first negotiation with respect to all future products Cosmo or its affiliates seek to market in the U.S. in the GI space, and (2) prohibit Cosmo from competing directly with the combined company in the GI space in the U.S. These terms will apply as long as Cosmo is entitled to designate a director to serve on the board of directors of Salix Pharmaceuticals, plc. Leadership The current officers and members of the executive team of Salix will continue to serve in their respective capacities within Salix Pharmaceuticals, plc. Salix Pharmaceuticals, plc’s board of directors will consist of the current directors of Salix plus Alessandro Della Chá, as Cosmo’s initial designated board member. Approvals The transaction, which has been unanimously approved by the boards of directors of both Salix and Cosmo, is subject to approval by Salix’s stockholders and the satisfaction of certain closing conditions, including antitrust approval in the U.S. The transaction does not require the vote of Cosmo’s shareholders. Advisors Salix’s exclusive financial advisor for the transaction is BofA Merrill Lynch, its legal advisors are Cadwalader, Wickersham & Taft, LLP and A&L Goodbody (Dublin), and its communications advisor is Teneo Strategy. Covington & Burling LLP advised Salix on licensing and supply agreements between Salix and Cosmo. Cosmo’s exclusive financial advisor is Jefferies International Limited, and its legal advisors are Procopio, Cory, Hargreaves & Savitch LLP and Byrne Wallace (Dublin). Salix Conference Call Salix will host a conference call at 6:00 p.m. EDT today, July 8, 2014, to discuss the transaction. Interested parties can access the conference call by way of webcast or telephone. The live webcast will be available at .Salix.com, along with related presentation materials shortly before the start of the call. The conference call can be accessed via phone by dialing (877) 856-1964 or (719) 325-4861, passcode 900519. A replay of the webcast will be available on the Company’s website following the event. Investor Days Salix will host an Investor Day on July 9, 2014, in New York from approximately 10:00 a.m. to 10:00 p.m. EDT. A live audio webcast of the event as well as related presentation materials will be accessible on the Salix web site at .salix.com. For those unable to join the live webcast, the presentation can be accessed via phone by dialing (877) 702-9041 or (719) 325-2171, passcode 616704. A replay of the presentation will be available on the Company’s website following the event. Cosmo will discuss the transaction at their Investor Day in Zurich on July 10, 2014. The Investor Day will be held from 17:00 CET onwards. Related presentation materials will be accessible on Cosmo’s web site at .cosmopharma.com. About Cosmo Cosmo Pharmaceuticals S.p.A. is a specialty pharmaceutical company headquartered in Lainate, Italy. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for the gastrointestinal tract, specifically inflammatory bowel diseases, colon infections and colon diagnosis, as well as selected topically treated skin disorders. Cosmo’s proprietary MMX® technology, designed to deliver active ingredients in a targeted manner in the colon, is at the core of the Company’s product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. Currently, Cosmo, through its appointed partners, has three products on the market and six in clinical development. For further information on Cosmo, please visit the Company’s website: .cosmopharma.com. About Salix Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license or acquire late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and commercialize them through Salix’s 500-member specialty sales force. Salix markets XIFAXAN® (rifaximin) tablets 200 mg and 550 mg, MOVIPREP® (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution, 100 g/7.5 g/2.691 g/1.015 g/5.9 g/4.7 g), OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) tablets, APRISO® (mesalamine) extended-release capsules 0.375 g, UCERIS® (budesonide) extended release tablets, for oral use, GIAZO® (balsalazide disodium) tablets, COLAZAL® (balsalazide disodium) Capsules, GLUMETZA® (metformin hydrochloride extended-release tablets) 500 mg and 1000 mg, ZEGERID® (omeprazole/sodium bicarbonate) Powder for Oral Suspension, ZEGERID® (omeprazole/sodium bicarbonate) capsules, METOZOLV® ODT (metoclopramide hydrochloride), RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, FULYZAQ® (crofelemer) delayed-release tablets, SOLESTA®, DEFLUX®, PEPCID® (famotidine) for Oral Suspension, DIURIL® (chlorothiazide) Oral Suspension, AZASAN® (azathioprine) tablets, USP, 75/100 mg, ANUSOL-HC® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg, CYCLOSET® (bromocriptine mesylate) tablets, FENOGLIDE® (fenofibrate) tablets. UCERIS (budesonide) rectal foam, RELISTOR®, LUMACAN™, RUCONEST®, RHB-106 and rifaximin for additional indications are under development. For full prescribing information and important safety information on Salix products, including BOXED WARNINGS for OSMOPREP, AZASAN, GLUMETZA and METOZOLV, please visit .salix.com, where Salix promptly posts press releases, SEC filings and other important information, or contact Salix at (919) 862-1000. Salix trades on the NASDAQ Global Select Market under the ticker symbol "SLXP". For more information, please visit our Website at .salix.com or contact Salix at (919)-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (.facebook.com/SalixPharma). Information on our Twitter feed, Facebook page and web site is not incorporated in our filingsith the SEC. No Offer or Solicitation This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval in any jurisdiction pursuant to the merger or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Important Additional Information and Where to Find It In connection with the proposed transaction and required stockholder approval, Cosmo Tech and Salix will file relevant materials with the Securities and Exchange Commission (the “SEC”), including a proxy statement/prospectus contained in a registration statement on Form S-4, which will be mailed to the stockholders of Salix after the registration statement is declared effective. The registration statement has not yet become effective. SALIX’S STOCKHOLDERS ARE ADVISED TO READ THE PROXY STATEMENT/PROSPECTUS, AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TRANSACTION, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. Salix’s stockholders may obtain a free copy of the proxy statement/prospectus, when it becomes available, and other documents filed by Salix, at the SEC’s web site at .sec.gov. Copies of Salix’s filings with the SEC may be obtained free of charge at the “Investors” section of Salix’s website at .salix.com or by contacting the Investor Relations Department of Salix at (919)-862-1000. Participants in the Solicitation Salix and its directors, executive officers and certain other members of its management and employees may be deemed to be participants in the solicitation of proxies from its stockholders in connection with the proposed transaction. Information regarding the interests of such directors and executive officers was included in Salix’s Proxy Statement for its 2014 Annual Meeting of Stockholders filed with the SEC on April 28, 2014 and information concerning the participants in the solicitation will be included in the proxy statement/prospectus relating to the proposed transaction when it becomes available. Each of these documents is, or will be, available free of charge at the SEC’s website at .sec.gov and from Salix on its website or by contacting the Investor Relations Department at the telephone number above. Cautionary Statement Regarding Forward-Looking Statements Please Note: The statements provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, our expectations might not be attained. Forward-looking statements are just predictions and are subject to known and unknown risks and uncertainties that could cause actual events or results to differ materially from expected results. Factors that could cause actual events or results to differ materially from those described in this press release include, among others: uncertainties as to the ability to successfully complete the proposed transaction in accordance with its terms and in accordance with the expected schedule; the possibility that competing offers will be made; the possibility that various closing conditions for the proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit or refuse to grant any approval required for the consummation of the proposed transaction; the unpredictability of the duration and results of regulatory review of New Drug Applications, Biologics License Agreements, and Investigational NDAs; generic and other competition in an increasingly global industry; litigation and the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties in an increasingly global industry; the cost, timing and results of clinical trials and other development activities involving pharmaceutical products; post-marketing approval regulation, including the ongoing Department of Justice investigation of Salix’s marketing practices; market acceptance for approved products; revenue recognition and other critical accounting policies; the need to acquire new products; general economic and business conditions; and other factors. Readers are cautioned not to place undue reliance on the forward-looking statements included in this press release, which speak only as of the date hereof. Salix does not undertake to update any of these statements in light of new information or future events, except as required by law. The reader is referred to the documents that Salix files from time to time with the SEC.

FDA Approves Anacor Pharmaceuticals’ KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails

. http://webmdreview.wordpress.com Buy Dolomite online Becoderm with no prescription About Diprolene (Betamethasone) with no prescription Duricef (Cefadroxil) with no Rx Buy Duphaston (Dydrogesterone) with no Rx

Xellia Pharmaceuticals Expands into the US with Acquisition of Manufacturing Plant

COPENHAGEN--(BUSINESS WIRE)--Xellia Pharmaceuticals (вЂ˜Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announced it has acquired Fresenius Kabi’s dedicated lyophilized (freeze-dried) vial manufacturing facility in Raleigh, North Carolina. The deal includes a continuous manufacturing and supply agreement with Fresenius Kabi USA. Financial details are not disclosed. The manufacturing site is located close to the world famous Research Triangle Park and is Xellia’s first facility in the US, significantly expanding the Company’s manufacturing capacity for injectable pharmaceutical products. Xellia intends to retain all ~80 staff currently employed at the site and will continue to manufacture certain products at the site for Fresenius Kabi. About Colofac (Mebeverine) with free Rx In the future, Xellia plans to employ more staff as it expands the site further. Commenting on the acquisition, Carl-Г…ke Carlsson, CEO Xellia said: “This is a great opportunity for us to expand our manufacturing capabilities into the US which is a key market for us. Buy Combivir (Lamivudine, Zidovudine) with no Rx We have great respect for Fresenius Kabi and its employees, and have been in partnership with the company for years as a preferred, trusted supplier of active pharmaceutical ingredients. Buy Clomid (Clomiphene) with free prescription I believe this acquisition will be a win-win situation, benefiting both companies and our customers.” “This agreement is part of our global strategy to optimize our manufacturing and supply network,” said John Ducker, president and CEO, Fresenius Kabi USA. Avandaryl without prescription “Both companies are committed to assure a smooth and seamless transition for customers and employees. Buy Creatine Supplements online This transaction will have no impact on Fresenius Kabi’s ability to meet customer demand for the products we currently manufacture at the Raleigh site and we continue to work closely with the FDA to alleviate US drug shortages.” Xellia is increasingly moving on from its origins as a manufacturer of active pharmaceutical ingredients (APIs) to better serve its global customer base of over 500 pharmaceutical companies by supplying the finished dosage form (FDF) of its drugs. http://webmdreview.wordpress.com This acquisition is part of the latest phase of Xellia’s on-going global expansion plans which include an investment of $2.0 million at the Company’s Product and Innovation R&D Centre of Excellence in Zagreb, Croatia in May. - Ends - About Xellia Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, Hungary and China, and currently employs over 900 people. Xellia is a leading supplier of Vancomycin and Colistimethate Sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Xellia is also developing novel antibiotics effective against MDR Gram-negative bacteria in a development project with SINTEF Materials and Chemistry (Trondheim) and the Statens Serum Institut (Copenhagen), supported by a grant from the Research Council of Norway. Since July 2013, Xellia has been wholly owned by Novo A/S, the holding Company of the Novo Group. Further information about Xellia can be found at: .xellia.com. About Fresenius Kabi Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The Company’s North America headquarters is in Lake Zurich, Illinois. In the United States, Fresenius Kabi (.fresenius-kabi.us) markets a broad portfolio of injectable and specialty pharmaceutical products with a focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets for use in hospitals, long-term care facilities, alternate care sites and clinics.

Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, DaklinzaВ® (daclatasvir) and SunvepraВ® (asunaprevir) Dual Regimen

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza® (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), and Sunvepra® (asunaprevir), a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options. The Daklinza+Sunvepra Dual Regimen is Japan’s first all-oral, interferon- and ribavirin-free treatment regimen for patients with genotype 1 chronic hepatitis C virus (HCV) infection, including those with compensated cirrhosis. “Japan has a unique hepatitis C patient population, many of whom are older and have been unable to take, or respond to, traditional therapies, so we have a real sense of urgency to treat these patients now,” said a lead study investigator Kazuaki Chayama of Hiroshima University in Japan. “The approval of the Daklinza+Sunvepra Dual Regimen offers for the first time a treatment option that addresses many of the unmet needs for our HCV patients.” Of the 1.2 million people living with HCV in Japan, approximately 70% have genotype 1b. Further, a significant number of patients with HCV in Japan are over the age of 65, leading to more disease-related complications and a decreased likelihood of tolerating interferon-based therapies, the historical standard of care for treating HCV. “The approval of Daklinza+Sunvepra in Japan reflects our strategic focus on developing a treatment option that meets the needs of the Japanese HCV patient population,” said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. About Colofac (Mebeverine) with free Rx “This milestone underscores the company’s commitment to delivering innovative medicines to patients with the highest unmet needs, and we believe Daklinza-based regimens will play a significant role in the evolution of HCV treatment for patients in Japan, and globally.” The Daklinza+Sunvepra Dual Regimen The indications for Daklinza and Sunvepra in Japan are for the improvement of viraemia in either of the following patients with chronic hepatitis C genotype 1, or chronic hepatitis C genotype 1 with compensated cirrhosis: (1) patients who are ineligible or intolerant to interferon-based therapy, and (2) patients who have failed to respond to interferon-based therapy. The approval is supported by results from a Phase III study demonstrating that the 24-week regimen of Daklinza and Sunvepra achieved overall SVR24 (sustained virologic response 24 weeks after the end of treatment; a functional cure) among 84.7% of Japanese HCV patients with genotype 1b. Buy Combivir (Lamivudine, Zidovudine) with no Rx Among patients 65 years of age or older who were either interferon-ineligible or intolerant, 91.9% achieved SVR24. Buy Clomid (Clomiphene) with free prescription Further, patients with compensated cirrhosis present at baseline had overall SVR24 rates of 90.9%. The regimen used in the Phase III study resulted in low rates of discontinuation (5%) due to adverse events (AEs). Avandaryl without prescription In addition, the rate of serious adverse events (SAEs) was low (5.9%) and few SAEs were experienced by more than one patient. Buy Creatine Supplements online Nasopharyngitis was the most common AE in the study (30.2%). Results from the HALLMARK-Dual study, the Phase III multinational clinical trial investigating the Daklinza+Sunvepra Dual Regimen among genotype 1b HCV patients, demonstrated similar results to the Japan registration study and support filings in countries that have a high prevalence of genotype 1b, such as Korea and Taiwan. About Bristol-Myers Squibb’s HCV Portfolio Bristol-Myers Squibb’s research efforts are focused on advancing late-stage compounds to deliver the most value to patients with hepatitis C. http://webmdreview.wordpress.com At the core of our pipeline is daclatasvir, a potent pan-genotypic NS5A complex inhibitor (in vitro), which continues to be investigated in multiple treatment regimens and in people with co-morbidities, and is undergoing regulatory review in the U.S. and Europe. Daclatasvir is being studied in combination with sofosbuvir in high unmet need patients, such as pre- and post-transplant patients, HIV/HCV co-infected patients, and patients with genotype 3, as part of the ongoing Phase III ALLY Program. In 2014, the U.S. Food and Drug Administration (FDA) granted Bristol-Myers Squibb’s investigational Daclatasvir+Asunaprevir Dual Regimen Breakthrough Therapy Designation for use as a combination therapy in the treatment of genotype 1b HCV infection. In 2013, Bristol-Myers Squibb’s investigational all-oral 3DAA Regimen (daclatasvir/asunaprevir/BMS-791325) also received Breakthrough Therapy Designation in the U.S., which helped to expedite the start of the ongoing Phase III UNITY Program. Study populations include non-cirrhotic naïve, cirrhotic naïve and previously treated patients. The daclatasvir 3DAA regimen is being studied as a fixed-dose-combination treatment with twice daily dosing. About Hepatitis C Globally, there are 150 million people infected with HCV, with genotype 1 being the most prevalent. Hepatitis C is a virus that infects the liver and is transmitted through direct contact with infected blood and blood products. Up to 90 percent of those infected with hepatitis C will not spontaneously clear the virus and will become chronically infected. According to the World Health Organization, 20 percent of people with chronic hepatitis C will develop cirrhosis and, of those, about 5 to 7 percent of patients may ultimately die of the consequences of infection. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit .bms.com or follow us on Twitter at twitter.com/bmsnews. Bristol-Myers Squibb Forward Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that daclatasvir or asunaprevir or any other compounds mentioned in this release will receive regulatory approval in other countries or that they will become commercially successful products. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb s Annual Report on Form 10-K for the year ended December 31, 2013, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Research and Markets Italy Dry Eye Syndrome Market Highlights - 2014

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/gwwvh3/italy_dry_eye) has announced the addition of the "Italy Dry Eye Syndrome Market Highlights - 2014" report to their offering. The latest research, Italy Dry Eye Syndrome Market Highlights - 2014 , provides Italy dry eye syndrome market analysis, competitive landscape, and dry eye syndrome drug sales forecast in Italy. The research includes Italy dry eye syndrome market size estimates for 2013, market share forecast for six years to 2019, dry eye syndrome drugs market share, dry eye syndrome drugs sales estimates, dry eye syndrome drugs sales forecast, and dry eye syndrome late stage pipeline products. This research helps executives track competitor drugs sales and market share in Italy dry eye syndrome market. It supports decision making in R&D to long term marketing strategies. The report can be used for evaluating business opportunities, formulating business development strategies, and product positioning in the Italy dry eye syndrome market. Highlights of the Research: Marketed Dry Eye Syndrome Drugs in Italy Italy Dry Eye Syndrome Market Analysis Dry Eye Syndrome Drugs Sales Analysis in Italy Competitive Landscape in Italy Dry Eye Syndrome market Dry Eye Syndrome Late Stage Pipeline Italy Dry Eye Syndrome Market Forecast Dry Eye Syndrome Drugs Sales Forecast in Italy Future Competitive Landscape Key Topics Covered: 1. Dry Eye Syndrome - Disease Definition 2. Adalat Cc (Nifedipine) without prescription Marketed Dry Eye Syndrome Drugs in Italy 3. Buy Advair Diskus (Fluticasone-Salmeterol) with no Rx Italy Dry Eye Syndrome Market Analysis 4. Advair Diskus (Fluticasone, Salmeterol) Competitive Landscape in Italy Dry Eye Syndrome Market 4a. Buy Abamune with free prescription Drugs Market Share in Italy Dry Eye Syndrome Market 4b. Buy Age - Brown Spots online Generics Market Share in Italy Dry Eye Syndrome Market 4c. http://webmdreview.wordpress.com Dry Eye Syndrome Phase 3 Clinical Trial Pipeline Molecules 5. Italy Dry Eye Syndrome Market - Future Market Outlook 5a. Italy Dry Eye Syndrome Market Size Forecast 5b. Drug Sales Forecast in Italy Dry Eye Syndrome Market 5c. Drugs Market Share in Italy Dry Eye Syndrome Market For more information visit .researchandmarkets.com/research/gwwvh3/italy_dry_eye

Snooze-it or loose-it

. http://webmdreview.wordpress.com Buy Age - Brown Spots online Buy Abamune with free prescription Advair Diskus (Fluticasone, Salmeterol) Buy Advair Diskus (Fluticasone-Salmeterol) with no Rx Adalat Cc (Nifedipine) without prescription eep deprivation has long been associated with negative health impacts such as workplace accidents and automobile accidents, obesity, high blood pressure, type 2 diabetes, depression, heart attacks and strokes according to the US Centers for Disease Control and Prevention (CDC). USA Today has reported that CDC data show 28% of US adults sleep six hours or less per night, leading the organisation to describe insufficient sleep “a public health epidemic.” Sleep is now considered to be “one of the components of a three-legged stool of wellness: nutrition, exercise and sleep,” says Safwan ...

Quintiles Completa la AdquisiciГіn de Encore Health Resources

RESEARCH TRIANGLE PARK, CAROLINA DEL NORTE--(BUSINESS WIRE)--Quintiles anunció hoy que ha completado la adquisición de Encore Health Resources (Encore), un líder en la industria de análisis de información sanitaria y servicios de consultoría de tecnología enfocado en los proveedores de salud. “Estamos muy contentos de haber completado la adquisición de Encore”, señaló Scott Evangelista, Presidente de Soluciones y Servicios Comerciales Integrados en Quintiles. “La incorporación de Encore mejora enormemente nuestra experiencia en registros electrónicos de salud, un área que sigue creciendo en importancia a medida que los pagadores, proveedores y clientes biofarmacéuticos aumentan su enfoque en la evidencia del mundo real. Estamos muy contentos de trabajar junto al equipo de Encore y de aprovechar los conocimientos que cada organización posee para ayudar a nuestros clientes a mejorar sus probabilidades de éxito”. Ahora conocida como “Encore, una compañía Quintiles”, Encore operará como parte del segmento de Servicios Integrados de Salud de Quintiles. Acerca de Quintiles Quintiles (NYSE: Q), una compañía Fortune 500, es el mayor proveedor mundial de servicios de desarrollo biofarmacéutico y tercerización comercial. Con una red de más de 29 000 empleados, que realizan negocios en aproximadamente 100 países, hemos colaborado en el desarrollo y en la comercialización de los 100 medicamentos más vendidos del mercado en 2013. En Quintiles aplicamos la amplitud y profundidad de nuestra oferta de servicios, junto con una amplia experiencia terapéutica, científica y analítica para ayudar a nuestros clientes a navegar en el cada vez más complejo ámbito de la atención de la salud, a medida que ellos tratan de mejorar la eficiencia y la eficacia en el logro de mejores resultados en materia de cuidado de la salud. About Advair Diskus (Fluticasone-Salmeterol) Para obtener más información acerca de Quintiles, visite .quintiles.com. Declaraciones a futuro Este comunicado de prensa contiene declaraciones a futuro dentro del significado de la Sección 27A de la Ley de valores (Securities Act) de 1933 y la Sección 21E de la Ley de Intercambio de Valores (Securities Exchange Act) de 1934. About Aggrenox (Asiprin - Dipyridamole) with no Rx Estas declaraciones a futuro reflejan, entre otras cosas, las expectativas actuales y los resultados esperados de las operaciones de Quintiles, los cuales están sujetos a riesgos conocidos y desconocidos, incertidumbres y otros factores que pueden hacer que los resultados reales, rendimientos o logros, tendencias de mercado o resultados de la industria de Quintiles difieran, sustancialmente, de aquellos expresados ​​o implícitos en dichas declaraciones a futuro. Aggrenox (Asprin, Dipyridamole) with free Rx Por lo tanto, ninguna de las declaraciones contenidas en este documento que no sean declaraciones de hechos históricos pueden ser declaraciones a futuro y deben ser evaluadas como tales. Buy Abilify with free prescription Sin limitar lo anterior, las palabras “prevé”, “cree”, “estima”, “espera”, “tiene la intención de”, “puede”, “planea”, “proyecta”, “debería”, “guía”, “tiene el propósito de”, “hará” y las formas negativas de las mismas así como otras palabras y expresiones similares tienen el objetivo de identificar las declaraciones a futuro. Buy Air Fresheners online Estas declaraciones están sujetas a riesgos, incertidumbres y suposiciones, incluido nuestra capacidad para completar, integrar y lograr nuestros objetivos previstos con respecto a la propuesta de adquisición de Encore y aquellos descriptos en la sección titulada "Factores de Riesgo" en el informe anual de Quintiles en el Formulario 10-K para el año finalizado el 31 de diciembre de 2013, presentado ante la SEC el 13 de febrero de 2014, ya que estos factores pueden ser actualizados oportunamente en las presentaciones periódicas de Quintiles ante la SEC, que están disponibles en el sitio web de la SEC en .sec.gov. http://webmdconsult.wordpress.com Estos factores no deben interpretarse como exhaustivos y deben leerse, conjuntamente, con las otras declaraciones preventivas que se incluyen en este comunicado y en las presentaciones de Quintiles ante la SEC. Quintiles no asume responsabilidad alguna de actualizar públicamente las declaraciones a futuro después de la fecha de este comunicado, ya sea como resultado de nueva información, acontecimientos futuros o de cualquier otra forma, salvo en lo requerido por la ley. Haga clic aquí para suscribirse a las alertas móviles de Quintiles. El texto original en el idioma fuente de este comunicado es la versión oficial autorizada. Las traducciones solo se suministran como adaptación y deben cotejarse con el texto en el idioma fuente, que es la única versión del texto que tendrá un efecto legal.

Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS

Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.

“These data indicate that HDL therapy is complementary to LDL-c-lowering treatment and may represent a new therapy for addressing the unmet medical need in FH patients.”

Data are being presented at the Late Breaker Session at the European Atherosclerosis Society (EAS) Meetings in Madrid, Spain on June 2, 2014.

SAMBA clinical trial:
Proof-of-Mechanism data will be presented at the EAS from the SAMBA Phase II efficacy and safety trial in patients with Familial Primary Hypoalphalipoproteinemia (FPHA), a rare syndrome of severe HDL deficiency caused by mutations in the genes responsible for HDL synthesis /maturation and characterized by accelerated atherosclerosis.
This pharmacokinetic/pharmacodynamic trial, conducted by Principal Investigator, Erik S.G. Stroes, MD, PhD of the Department of Vascular Medicine at the Academic Medical Center (AMC) in Amsterdam, The Netherlands, Lotensin (Benazepril) with free prescription enrolled 7 FPHA patients in an open-label single-arm active-treatment study and assessed the efficacy of infused CER-001 engineered human apoA-I-containing pre-β HDL particles in reconstituting the endogenous Reverse Lipid Transport in individuals who have defects in the natural HDL pathway and facilitate elimination of cholesterol from the body.
The data from patients receiving CER-001 treatment on top of optimized standard of care LDL-c-lowering therapy showed that CER-001 performed the four steps of the Reverse Lipid Transport pathway: CER-001 increased cholesterol mobilization and esterification in the HDL fraction, and one month of treatment with 9 doses of CER-001 resulted in a statistically significant reduction in carotid artery Mean Vessel Wall Area, as measured by Magnetic Resonance Imaging (3T-MRI). CER-001 was well-tolerated.
Specific data from the study will be presented on Monday June 2, 2014 at 3:45pm in Madrid.
Dr. Stroes commented, "The results of this study support the future use of CER-001 for chronic administration aiming to reduce the elevated cardiovascular risk in low HDL patients with a high unmet clinical need."
MODE clinical trial:
Cerenis also reported that data from the MODE (Modifying Orphan Drug Evaluation) trial, a Phase II efficacy and safety study in patients with Homozygous Familial Hypercholesterolemia (HoFH), About Female Viagra (Sildenafil Citrate) with free prescription a rare disease of markedly elevated LDL-cholesterol (bad cholesterol) levels caused by genetic defects in the LDL-receptor pathway and characterized by premature atherosclerosis. Data will also be presented as a late-breaking clinical trial at the EAS.
The open-label single-arm active-treatment study in 23 patients with homozygous FH met the prespecified primary clinical endpoint in the modified Intention to Treat population, demonstrating a statistically significant reduction in carotid artery Mean Vessel Wall Area, as measured by Magnetic Resonance Imaging (3T-MRI), after 6-months of bi-weekly CER-001 treatment on top of optimized LDL-c-lowering therapy, including apheresis. CER-001 was well-tolerated.
Specific data from the study will be presented on Monday June 2, 2014 at 4:00pm in Madrid.
Dr. Kees Hovingh, the Principal Investigator of the MODE study, commented, Buy Diamox (Acetazolamide) with free prescription "These data indicate that HDL therapy is complementary to LDL-c-lowering treatment and may represent a new therapy for addressing the unmet medical need in FH patients."
John F. Paolini, MD, PhD, FACC, Chief Medical Officer of Cerenis, said, “CER-001 has been shown to offer an important benefit for patients suffering from accelerated cardiovascular disease caused by genetic defects at both ends of the spectrum of cholesterol homeostasis. The demonstrated safety profile observed in all studies performed thus far supports the use of CER-001 for chronic treatment in both these rare patient populations.”
Jean-Louis Dasseux, PhD, MBA, and CEO of Cerenis, concluded: “In all preclinical and clinical studies to date, CER-001 has been shown to perform the functions of natural HDL and the steps of the Reverse Lipid Transport Pathway leading to elimination of cholesterol from the body with a high degree of potency. The clinical benefit observed in these genetically challenged patients is further evidence supporting HDL therapy in the broader treatment of atherosclerosis. We are committed to continuing the development of CER-001 in these important rare disease clinical indications.”

About Cerenis Therapeutics
Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of novel HDL therapies for the treatment of cardiovascular and metabolic diseases. Acnederm with free Rx HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body. Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients, and drugs which increase HDL for patients with low HDL. Cerenis is well-positioned to become the leader in the HDL therapeutic market with a broad portfolio of programs in development.
Since its inception in 2005, the company raised €117 M in equity with top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and the FSI (Fund for Strategic Investment). €10,7M was also provided by OSEO, the French agency for innovation, to support the development of CER-001.
About CER-001
CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and charged phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL. Its mechanism of action is to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport.
Familial Primary Hypoalphalipoproteinemia (FPHA)
Hypoalphalipoproteinemia (“low HDL”), as a general term, has historically been defined clinically as an HDL-cholesterol (HDL-C) less than 40 mg/dL (1.0 mmol/L) in men, and less than 50 mg/dL (1.3 mmol/L) in women. Medical Questions and Answers A number of etiologies, often metabolic, can underlie a reduced circulating level of cholesterol in the HDL fraction, for example diabetes, Metabolic Syndrome, obesity, and lack of physical activity (thus called secondary hypoalphalipoproteinemia). In a very small percentage of the population, particularly amongst the patients with the very lowest HDL-C values, there are patients who have a genetic defect (thus called primary hypoalphalipoproteinemia) affecting either the constituent components of the pre-β particle, the process of pre-β particle synthesis, the steps leading to maturation into an alpha HDL particle, or the rates of catabolism – any of which alone or in combination can then result in an inherited condition of very low circulating HDL particle number.
Familial Primary Hypoalphalipoproteinemia (FPHA) includes patients with a range of individual mutations across the key genes involved in HDL particle production or maturation (apoA-I, ABCA1, LCAT) which are individually extremely rare (prevalence less than one in one million births in the homozygous form) but in both homozygous and heterozygous forms can act in an autosomal dominant manner to cause low apoA-I levels and low HDL particle numbers through either decreased production or increased clearance and premature destruction of HDL particles and ultimately result in accelerated atherosclerosis from a single final common pathophysiology of impaired Reverse Lipid Transport (RLT) and accumulation of cholesterol throughout the body, in particular, the vasculature. FPHA patients are at high risk of cardiovascular disease as a consequence of having inherited a virtually absent endogenous RLT system. Because of the specific characteristics and very limited available therapeutic approaches, FPHA remains an unmet medical need and a life-threatening condition.
Familial Hypercholesterolemia (FH)
Familial hypercholesterolemia (FH) is characterized by high cholesterol levels, specifically very high low-density lipoprotein (LDL) levels and early cardiovascular disease. Many patients have mutations in the LDLR gene that encodes the LDL receptor protein, which normally removes LDL from the circulation, or apolipoprotein B (ApoB), which is the part of LDL that binds with the receptor; mutations in other genes are rare. In homozygous familial hypercholesterolemia (HoFH), serum LDL-C levels may be elevated six-fold. Patients develop severe aortic stenosis and coronary heart disease by age 20 and normally do not respond adequately to drug or diet modification therapy. Although the existing therapies, including statins, cholesterol absorption inhibitors, and LDL apheresis, can significantly reduce circulating LDL-C, nevertheless, LDL-C still remains higher than that recommended by current treatment guidelines, and these patients continue to have cardiovascular events of MI, stroke, and death at an elevated rate. The prevalence of homozygous FH is approximately one in one million births.

Fraunhofer USA Center for Molecular Biotechnology Begins Clinical Trial of New Malaria Vaccine Approach

Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announced today that clearance was obtained from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND), Fraunhofer’s plant-derived malaria transmission-blocking vaccine (TBV), which targets the Pfs25 antigen, to proceed into the clinic in a Phase 1 safety and immunogenicity study.

“Entering this clinical trial is an important milestone”

Antibodies directed at Pfs25 can block transmission of the malaria parasite from mosquitoes to humans by preventing the parasite from developing in the mosquito. Elavil (Amitriptyline) pills In preclinical models, purified plant-derived virus-like particles containing Pfs25, in combination with the adjuvant Alhydrogel®, have been shown to induce antibodies that effectively block infection of mosquitoes that have fed on an infectious blood meal. Buy Eldepryl (Selegiline) If these results can be reproduced in humans, the vaccine approach may provide a strategy to interrupt malaria transmission and thereby contribute to reduction of the P. falciparum disease burden.
“Entering this clinical trial is an important milestone,” said Dr. Yusibov, Executive Director of FhCMB. Buy Ziac (Biosoprolol, Hydrochlorothiazide) “We have moved targets from molecular engineering all the way through to pilot scale manufacturing in plants under good manufacturing practices and evaluation in a Phase 1 clinical trial.”
Development of this malaria TBV is an effort to improve global health by supporting the development of critical platform technologies for delivering vaccines to malaria-endemic countries. Vitamins As part of the planned collaboration strategy, FhCMB, the PATH Malaria Vaccine Initiative (MVI) and Accelovance entered into an agreement to conduct a Phase 1 clinical trial.
“We are excited to see this promising new vaccine approach advance to clinical testing,” says Ashley J. Birkett, PhD, Director of MVI. “Vaccines that can induce immunity to break the cycle malaria parasite transmission between humans and mosquitoes have the potential important interventions to accelerate future elimination and eradication efforts.”
This Phase 1 clinical trial was initiated in early November and is being conducted by Accelovance.
About Fraunhofer
Fraunhofer USA is a subsidiary of Fraunhofer-Gesellschaft, a world leading applied R&D organization with 66 institutes and independent research units throughout Germany. Cardio & Blood Medications Customers Review Fraunhofer USA’s nine centers perform applied research under contract to government and industry.
Fraunhofer USA Center for Molecular Biotechnology is developing a safe, rapid and economical alternative for vaccine production. The Center conducts research in the area of plant biotechnology, utilizing new, cutting edge approaches to assist the diagnosis, prevention and treatment of human and animal diseases. With its GMP production facility, the Center provides the full complement of capabilities from target expression through Phase 1 and 2 clinical product development.